Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNurix Therapeutics Inc

Nurix Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
15.3 USD 0.46 ( 3.10%)
Last update at 2026-11-06T21:00:00Z
VOLUME
2968703
Market Cap
2576.90M

Momentum Score

…

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
14.79
Low
15.52
High
52 Week Price Range
8.20
Low
28.23
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
14.84
Dividend Yield
-
Revenue TTM
36.77M
Revenue Per Share
0.37
Gross Profit TTM
-304.17M
Debt / Equity
0.10
ROE
-80.30%
Net Debt
-191.23M
ROCE
-43.83%
Diluted EPS TTM
-3.37

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-11-30 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Type yearly yearly yearly yearly yearly
Date 2025-11-30 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Income before tax -263.70M -193.30M -143.95M -180.36M -117.06M
Net income -264.46M -193.57M -143.95M -166.04M -117.19M
Selling general administrative 52.74M 45.94M 42.90M 38.00M 31.20M
Selling and marketing expenses - - 6.12M - -
Gross profit 65.12M -167.08M -112.16M 38.63M 29.75M
Reconciled depreciation 18.86M 16.43M 13.65M 10.81M 6.08M
Ebit -263.70M -193.30M -143.95M -194.68M -123.97M
Ebitda -244.84M -185.28M -137.81M -183.87M -117.89M
Depreciation and amortization 18.86M 8.02M 6.13M 10.81M 6.08M
Non operating income net other - - - 3.51M 0.82M
Operating income -285.67M -213.03M -155.06M -183.87M -117.89M
Other operating expenses 369.65M 267.58M 232.05M 222.49M 147.64M
Interest expense - - - -14.31M 6.91M
Tax provision 0.76M 0.27M 0.00M 0.00M 0.13M
Interest income 21.97M 19.73M 11.12M 3.51M 0.82M
Net interest income 21.97M 19.73M 11.12M 3.51M 0.82M
Income tax expense 0.76M 0.27M 13.49M -14.31M 0.13M
Total revenue 83.98M 54.55M 76.99M 38.63M 29.75M
Total operating expenses 350.79M 45.94M 42.90M 222.49M 147.64M
Cost of revenue 18.86M 221.63M 189.15M - -
Total other income expense net 21.97M 19.73M 11.12M 3.51M 0.82M
Net income from continuing ops -264.46M -193.57M -143.95M -180.36M -117.19M
Net income applicable to common shares - - - -180.36M -117.19M
Breakdown 2025-11-30 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Type yearly yearly yearly yearly yearly
Date 2025-11-30 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Total assets 688.13M 669.34M 364.54M 416.76M 476.77M
Other current assets 13.88M 8.30M 6.79M 9.31M 9.19M
Total liab 149.39M 142.35M 164.05M 113.06M 134.47M
Total stockholder equity 538.75M 526.99M 200.49M 303.70M 342.30M
Deferred long term liab - - - 0.50M 0.50M
Other current liab 54.85M 36.76M 24.97M 22.43M 14.55M
Common stock 0.10M 0.08M 0.05M 0.05M 0.04M
Capital stock 0.10M 0.08M 0.05M 0.05M 0.04M
Retained earnings -1003.23M -738.77M -545.20M -401.25M -220.89M
Other liab - - - 35.97M 59.02M
Other assets - - - 4.92M 3.12M
Cash 246.96M 110.00M 54.63M 64.47M 80.51M
Total current liabilities 86.47M 95.85M 86.96M 70.66M 66.26M
Current deferred revenue 17.58M 38.36M 48.10M 37.63M 41.21M
Net debt -191.23M -81.69M -24.01M -52.51M -67.47M
Short term debt 2.82M 8.01M 7.49M 5.53M 3.85M
Short long term debt total 55.73M 28.30M 30.61M 11.96M 13.04M
Other stockholder equity 1541.77M 1265.54M 746.30M 709.22M 563.76M
Property plant equipment - - - 17.16M 25.34M
Total current assets 606.82M 619.39M 295.50M 318.45M 311.12M
Long term investments - 0.00M 7.42M 63.88M 137.19M
Net tangible assets - - - 303.70M 342.30M
Short term investments 345.98M 499.59M 233.28M 244.67M 215.21M
Net receivables - 1.50M 0.80M 1.10M 6.20M
Accounts payable 11.21M 11.48M 6.40M 5.06M 6.65M
Accumulated other comprehensive income 0.10M 0.15M -0.66M -4.32M -0.61M
Common stock total equity - - - 0.05M 0.04M
Retained earnings total equity - - - -401.25M -220.89M
Non currrent assets other 8.31M 4.06M 3.82M 4.92M 3.12M
Non current assets total 81.32M 49.96M 69.04M 98.31M 165.65M
Capital lease obligations 55.73M 28.30M 30.61M 11.96M 13.04M
Breakdown 2025-11-30 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Type yearly yearly yearly yearly yearly
Date 2025-11-30 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Investments 161.85M -257.71M 68.30M 39.44M -102.59M
Change to liabilities - - - 7.57M 8.34M
Total cashflows from investing activities 147.85M -257.71M 68.30M 27.20M -108.25M
Total cash from financing activities 238.64M 485.67M 3.22M 117.19M 153.88M
Change to operating activities - - - 1.52M -4.37M
Net income -264.46M -193.57M -143.95M -180.36M -117.19M
Change in cash 137.03M 55.37M -9.85M -15.42M -38.73M
Begin period cash flow 110.00M 55.53M 65.38M 80.79M 119.53M
End period cash flow 247.93M 110.90M 55.53M 65.38M 80.79M
Total cash from operating activities -249.47M -172.58M -81.36M -159.81M -84.36M
Issuance of capital stock 234.76M 478.50M 0.00M 19.40M 150.16M
Depreciation 18.86M 16.43M 13.65M 10.81M 6.08M
Change to inventory - - - - 6.77M
Change to account receivables - 0.00M 0.00M 6.00M -6.00M
Sale purchase of stock - - - 117.19M 153.88M
Other cashflows from financing activities - 7.17M 3.22M 97.79M 3.73M
Change to netincome - - - 28.34M 17.63M
Capital expenditures 14.00M 9.27M 8.40M 12.24M 5.66M
Change receivables - - - 6.00M -6.00M
Cash flows other operating - - - -27.13M 10.60M
Cash and cash equivalents changes - - - -15.42M -38.73M
Change in working capital -31.60M -18.40M 20.12M -19.02M 9.11M
Stock based compensation 37.97M 33.93M 33.67M 28.13M 15.80M
Other non cash items -10.23M -10.97M -4.87M 0.64M 1.83M
Free cash flow -263.47M -181.86M -89.77M -172.05M -90.03M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NRIX
Nurix Therapeutics Inc		 0.46
3.10%		 15.30 - - 70.09 6.58 61.54 -3.35
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Nurix Therapeutics Inc

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

1600 Sierra Point Parkway, Brisbane, CA, United States, 94005

415 660 5320

https://www.nurixtx.com

317

Name Title Year Born
Dr. Arthur T. Sands M.D., Ph.D. CEO, Pres & Director 1962
Mr. Johannes Van Houte Chief Financial Officer 1966
Ms. Stefani A. Wolff COO & Exec. VP of Product Devel. 1962
Dr. Gwenn M. Hansen Ph.D. Chief Scientific Officer 1971
Dr. Christine Ring Gen. Counsel & Sec. 1965
Dr. John Kuriyan Ph.D. Founder & Member of Scientific Advisory Board NA
Dr. Michael Rapé Ph.D. Founder & Member of Scientific Advisory Board NA
Prof. Arthur Weiss M.D., Ph.D. Founder & Member of Scientific Advisory Board NA
Mr. Howard A. Simon J.D., Esq., SPHR VP of Operations & Corp. Counsel 1959
Rita Kwong Sr. Accounting Mang. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…